lundi 26 octobre 2015

Onco Actu du 26 octobre 2015 (2/2)

2. Etiologie

Antioxidants, free radicals and melanoma spread – what’s going on? [Cancer Research UK]

Antioxidants May Aid Cancer [The Scientist Magazine]

2.6 Etiologie - Environnement

International Thyroid Congress Highlights Latest Research on Cancer Risk Factors and New Therapies for Thyroid Disease [American Thyroid Association]

5. Traitements

Learning From Dogs With Cancer [NY Times]

Looking Back at Sutent’s Development: Problems or Not? [In the Pipeline]

5.10 Traitements - Essais

ImmunoGen, Roche gastric cancer drug fails study [Reuters]

5.12 Immunothérapies

With New Startup, Caperna, Moderna Gets in on Cancer Vaccine Buzz [Xconomy]

Discovery opens door to new strategy for cancer immunotherapy [Dana-Farber Cancer Institute]

Biotech billionaire Soon-Shiong strikes $50M deal for control of cancer vaccines [FierceBiotech]

Big science: Upstart Gritstone bags $102M to go after a new immuno-oncology target [FierceBiotech]

5.2.1 Pharma - Partenariats

Lilly and AstraZeneca Expand Immuno-Oncology Research Collaboration with New Combinations [Lilly]

MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA® (pembrolizumab) for Advanced Gastric Cancer [Merck]

5.2.2 Pharma - Fusions & Acquisitions

Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma [Novartis]

5.2.3 Pharma - économie

Synta gets decimated after its lead cancer drug comes up short in Phase III [FierceBiotech]

Synta halts study of lung cancer treatment, stock plummets [Reuters]

5.3 Traitements - FDA, EMA,...

Pfizer’s Inotuzumab Ozogamicin Receives FDA Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia (ALL) [Pfizer]

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag [FierceBiotech]

Is 1 in 7 Odds a Breakthrough? Is it Even Promising? [HealthNewsReview]

Study: Two-thirds of new cancer drugs not found to extend life [Journal Sentinel]

Researchers Question FDA's Use of Surrogate Endpoints for Cancer Drug Approvals [RAPS]

The problem with using surrogate markers to approve cancer drugs [Pharmalot]

5.3.4 Traitements - AMM (FDA, EMA)

J&J's cancer drug finally wins FDA approval after 6 years of delay [FierceBiotech]

Amgen wins EU green light for first virus-based cancer drug [Reuters]

First oncolytic immunotherapy medicine recommended for approval [EMA]

FDA approves new therapy for certain types of advanced soft tissue sarcoma [FDA]

U.S. FDA Approves YONDELIS® (trabectedin) for the Treatment of Patients with Unresectable or Metastatic Liposarcoma or Leiomyosarcoma, Two Common Subtypes of Soft Tissue Sarcoma [Johnson & Johnson]

FDA approves new treatment for advanced pancreatic cancer [FDA]

FDA clears J&J's chemotherapy for certain soft tissue sarcomas [Reuters]

FDA clears Merrimack's pancreatic cancer drug with warning [Reuters]

5.4 Traitements - Economie

We need drug pricing changes , agree Cancer Drugs Fund chief and pharma [PharmaPhorum]

To reduce the cost of drugs, consider reference pricing [The Incidental Economist]

NCCN Unveils Evidence Blocks for CML and Multiple Myeloma [NCCN]

U.S. oncology group rates blood cancer regimens, including cost [Reuters]

U.S. drug prices should reflect value to patients: expert panel [Reuters]

5.9.1 ASTRO

A subset of patients with metastatic melanoma achieves clinical benefit from combination of immunotherapy and radiation therapy [ASTRO]

6.9 Controverses

Claims rhubarb pigment 'could help cancer crumble' [NHS Choices]